

Rocco Piazza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9191590/publications.pdf>

Version: 2024-02-01

112
papers

4,183
citations

201385

27
h-index

118652

62
g-index

116
all docs

116
docs citations

116
times ranked

5598
citing authors

#	ARTICLE	IF	CITATIONS
1	LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data. <i>Journal of Computational Science</i> , 2022, 58, 101523.	1.5	14
2	Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution. <i>Virus Evolution</i> , 2022, 8, veac026.	2.2	15
3	Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. <i>American Journal of Hematology</i> , 2022, 97, 1075-1085.	2.0	13
4	Variant calling from scRNA-seq data allows the assessment of cellular identity in patient-derived cell lines. <i>Nature Communications</i> , 2022, 13, 2718.	5.8	5
5	Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
6	Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience. <i>Leukemia Research</i> , 2022, 118, 106861.	0.4	0
7	Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency. <i>Blood</i> , 2021, 137, 493-499.	0.6	26
8	The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner. <i>Cancers</i> , 2021, 13, 341.	1.7	4
9	Impact of <i>ETNK1</i> somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1877598.	0.3	3
10	Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity. <i>IScience</i> , 2021, 24, 102116.	1.9	64
11	VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples. <i>Patterns</i> , 2021, 2, 100212.	3.1	26
12	14q32 rearrangements deregulating <i>BCL11B</i> mark a distinct subgroup of T and myeloid immature acute leukemia. <i>Blood</i> , 2021, 138, 773-784.	0.6	19
13	Case Report: Hypomorphic Function and Somatic Reversion in <i>DOCK8</i> Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. <i>Frontiers in Immunology</i> , 2021, 12, 673487.	2.2	5
14	Human Chromosome 18 and Acrocentrics: A Dangerous Liaison. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5637.	1.8	0
15	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103105.	0.5	3
16	SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome. <i>Nature Communications</i> , 2021, 12, 4050.	5.8	24
17	Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. <i>Blood</i> , 2021, 138, 2093-2105.	0.6	37
18	Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. <i>Cancers</i> , 2021, 13, 4422.	1.7	11

#	ARTICLE	IF	CITATIONS
19	HIF1A: A Putative Modifier of Hemochromatosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1245.	1.8	5
20	NKG2A expression identifies a subset of human V α 2 T β cells exerting the highest antitumor effector functions. <i>Cell Reports</i> , 2021, 37, 109871.	2.9	30
21	VirMutSig: Discovery and assignment of viral mutational signatures from sequencing data. <i>STAR Protocols</i> , 2021, 2, 100911.	0.5	3
22	CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2276-2276.	0.6	8
23	Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 756348.	1.3	5
24	An Imatinib-“non-“responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 71-74.	0.2	1
25	The role of bosutinib in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 4395-4408.	1.1	26
26	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. <i>Nature Communications</i> , 2020, 11, 5938.	5.8	22
27	A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. <i>Leukemia Research</i> , 2020, 97, 106441.	0.4	8
28	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	1.2	14
29	Phase two study of crizotinib in patients with anaplastic lymphoma kinase (<sc>ALK</sc>)“positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, E319-E321.	2.0	21
30	APOL1 polymorphism modulates sphingolipid profile of human podocytes. <i>Glycoconjugate Journal</i> , 2020, 37, 729-744.	1.4	3
31	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	0.6	13
32	An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 523.	2.0	15
33	Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients. <i>Scientific Reports</i> , 2020, 10, 542.	1.6	4
34	Germline TP53 Mutation in an Adolescent With CMML/Atypical CML and Familial Cancer Predisposition. <i>HemaSphere</i> , 2020, 4, e460.	1.2	2
35	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. <i>Blood</i> , 2020, 136, LBA-5-LBA-5.	0.6	1
36	A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, e257-e259.	0.5	23

#	ARTICLE	IF	CITATIONS
37	Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). <i>Hematological Oncology</i> , 2019, 37, 505-507.	0.8	2
38	<i>De novo UBE2A</i> mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. <i>Haematologica</i> , 2019, 104, 1789-1797.	1.7	21
39	A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 2481-2494.	3.3	4
40	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. <i>Blood</i> , 2019, 134, 29-29.	0.6	2
41	Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients. <i>Blood</i> , 2019, 134, 1714-1714.	0.6	0
42	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. <i>Neoplasia</i> , 2018, 20, 467-477.	2.3	13
43	Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling. <i>Cancers</i> , 2018, 10, 509.	1.7	3
44	Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. <i>Cancer Research</i> , 2018, 78, 6866-6880.	0.4	69
45	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. <i>Nature Communications</i> , 2018, 9, 2192.	5.8	66
46	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. <i>Blood</i> , 2018, 132, 461-461.	0.6	8
47	OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. <i>Scientific Reports</i> , 2017, 7, 46290.	1.6	31
48	Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. <i>European Journal of Cancer</i> , 2017, 77, 48-56.	1.3	74
49	How "precise" is precision medicine in hematology?. <i>Haematologica</i> , 2017, 102, 4-6.	1.7	7
50	Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. <i>American Journal of Hematology</i> , 2017, 92, E623-E625.	2.0	13
51	Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 27889-27898.	0.8	15
52	Chronic myeloid leukemia: Second-line drugs of choice. <i>American Journal of Hematology</i> , 2016, 91, 67-75.	2.0	33
53	OncoScore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis. <i>Blood</i> , 2016, 128, 3075-3075.	0.6	1
54	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115

#	ARTICLE	IF	CITATIONS
55	Age and d<sc>PCR</sc> can predict relapse in <sc>CML</sc> patients who discontinued imatinib: The <sc>ISAV</sc> study. American Journal of Hematology, 2015, 90, 910-914.	2.0	181
56	RNAâ€seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. American Journal of Hematology, 2015, 90, E227-8.	2.0	2
57	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	0.6	19
58	Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALKâ€Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research, 2015, 13, 775-783.	1.5	52
59	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. Journal of Hematology and Oncology, 2015, 8, 81.	6.9	20
60	BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Molecular Cancer, 2015, 14, 132.	7.9	35
61	Imatinibâ€A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncology, 2015, 1, 143.	3.4	16
62	How <sc>I</sc> treat newly diagnosed chronic myeloid leukemia in 2015. American Journal of Hematology, 2015, 90, 156-161.	2.0	18
63	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. Blood, 2015, 126, 2775-2775.	0.6	3
64	NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget, 2015, 6, 5720-5734.	0.8	29
65	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes Î± mediated p53 nuclear exclusion. Oncotarget, 2015, 6, 25217-25225.	0.8	16
66	ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. Blood, 2015, 126, 3652-3652.	0.6	1
67	Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2014, 15, 701-710.	0.9	16
68	Whole-Exome Sequencing Data â€ Identifying Somatic Mutations. , 2014, , 419-427.		0
69	Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinaseâ€Positive Lymphoma Patients. Journal of the National Cancer Institute, 2014, 106, djt378.	3.0	207
70	Firstâ€line treatment of 102 chronic myeloid leukemia patients with imatinib: A longâ€term single institution analysis. American Journal of Hematology, 2014, 89, E184-7.	2.0	24
71	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. Blood, 2014, 124, 813-813.	0.6	4
72	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	9.4	359

#	ARTICLE	IF	CITATIONS
73	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. <i>Neoplasia</i> , 2013, 15, 511-517.	2.3	44
74	Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. <i>Carcinogenesis</i> , 2013, 34, 2767-2773.	1.3	40
75	Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. <i>Molecular Genetics & Genomic Medicine</i> , 2013, 1, 246-259.	0.6	17
76	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e74825.	1.1	20
77	High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients. <i>Blood</i> , 2013, 122, 368-368.	0.6	10
78	SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2598-2598.	0.6	1
79	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 4040-4040.	0.6	0
80	FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. <i>Nucleic Acids Research</i> , 2012, 40, e123-e123.	6.5	29
81	A Bioinformatics Procedure to Identify and Annotate Somatic Mutations in Whole-Exome Sequencing Data. <i>Lecture Notes in Computer Science</i> , 2012, , 73-82.	1.0	0
82	Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2012, 87, E125-8.	2.0	93
83	Integrated Analysis of Whole-Exome Sequencing and Micrnas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia. <i>Blood</i> , 2012, 120, 3727-3727.	0.6	1
84	Choosing the right TKI for chronic myeloid leukemia: When the truth lies in the long-term safety and efficacy. <i>American Journal of Hematology</i> , 2011, 86, 531-532.	2.0	8
85	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	3.0	362
86	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. <i>PLoS ONE</i> , 2011, 6, e28162.	1.1	25
87	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years. <i>Blood</i> , 2011, 118, 3766-3766.	0.6	0
88	CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis. <i>Blood</i> , 2011, 118, 2739-2739.	0.6	0
89	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. <i>Blood</i> , 2010, 116, 3013-3022.	0.6	110
90	BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. <i>Leukemia</i> , 2010, 24, 1445-1449.	3.3	37

#	ARTICLE	IF	CITATIONS
91	Reply to P. Laneuville et al. Journal of Clinical Oncology, 2010, 28, e172-e172.	0.8	7
92	Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. Journal of Clinical Oncology, 2009, 27, 469-471.	0.8	365
93	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 2009, 124, 1990-1996.	2.3	29
94	Insights from a Transgenic Mouse Model on the Role of SLC26A2 in Health and Disease. Novartis Foundation Symposium, 2008, , 193-212.	1.2	4
95	BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients. Blood, 2008, 112, 3204-3204.	0.6	2
96	Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants. Blood, 2008, 112, 3220-3220.	0.6	0
97	NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood, 2007, 110, 2600-2609.	0.6	34
98	In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine, 2007, 13, 13-14.	15.2	54
99	The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells, Molecules, and Diseases, 2006, 37, 111-115.	0.6	9
100	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 2006, 66, 11314-11322.	0.4	352
101	Insights from a transgenic mouse model on the role of SLC26A2 in health and disease. Novartis Foundation Symposium, 2006, 273, 193-206; discussion 206-12, 261-4.	1.2	2
102	Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia, 2005, 19, 132-134.	3.3	15
103	Imatinib dose increase up to 1200â€‰mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia, 2005, 19, 1985-1987.	3.3	9
104	Response to â€”D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patientsâ€”™ by Leguay et al. Leukemia, 2005, 19, 2333-2334.	3.3	1
105	A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Human Molecular Genetics, 2005, 14, 859-871.	1.4	116
106	Development of c-Kit-expressing Small-Cell Lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment. Journal of the National Cancer Institute, 2004, 96, 1723-1724.	3.0	5
107	Highly Sensitive Mutations Detection in BCR-ABL Positive Leukemia Prior and during Imatinib Treatment.. Blood, 2004, 104, 1985-1985.	0.6	1
108	Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncology, The, 2003, 4, 75-85.	5.1	349

#	ARTICLE	IF	CITATIONS
109	IN VITRO PROTEOGLYCAN SULFATION DERIVED FROM SULFHYDRYL COMPOUNDS IN SULFATE TRANSPORTER CHONDRODYSPLASIAS. Fetal and Pediatric Pathology, 2003, 22, 311-321.	0.3	8
110	Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood, 2003, 102, 1933-1935.	0.6	16
111	IN VITRO PROTEOGLYCAN SULFATION DERIVED FROM SULFHYDRYL COMPOUNDS IN SULFATE TRANSPORTER CHONDRODYSPLASIAS. Fetal and Pediatric Pathology, 2003, 22, 311-321.	0.3	4
112	EXT 1 Gene Mutation Induces Chondrocyte Cytoskeletal Abnormalities and Defective Collagen Expression in the Exostoses. Journal of Bone and Mineral Research, 2000, 15, 1489-1500.	3.1	28